Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K31/125—Camphor; Nuclear substituted derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
  • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/105—Aliphatic or alicyclic compounds
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/174—Vitamins
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K50/00—Feeding-stuffs specially adapted for particular animals
  • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
  • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

• the present invention relates to the use of canthaxanthin and/or at least one vitamin D metabolite, preferably 25-hydroxy vitamin D3 (25-OH D3), for improving breeder hatchability. More particularly the invention relates to the use of canthaxanthin and/or 25-hydroxy vitamin D3 in the manufacture of a feed or veterinary composition for improving hatchability in poultry.
• Applicant now surprisingly found that relatively high concentrations of essential nutrients in the embryo such as canthaxanthin or 25-OH-D3 supplied via maternal supplementation are related to improved hatchability, fertility and lower embryo mortality during the first phase of embryo development.
• Tritsch et al. disclose a feed premix composition of at least 25-OH D3 in an amount between 5% and 50% (wt/wt) dissolved in oil and an antioxidant, an agent encapsulating droplets of 25-OH D3 and oil, and a nutritional additive (e.g., Vitamin D3).
• the premix may be added to poultry, swine, canine, or feline food. This composition stabilizes 25- OH D3 against oxidation.
• Simoes-Nunes et al. discloses adding a combination of 25-OH Vitamin D3 and Vitamin D3 to animal feed. In particular, about 10 ⁇ g/kg to about 100 ⁇ g/kg of 25-OH Vitamin D3 and about 200 IU/kg to about 4,000 IU/kg of Vitamin D3 are added to swine feed. This addition improves the pig's bone strength.
• Stark et al. disclose adding a combination of 25-OH Vitamin D3 and Vitamin D3 to poultry feed to ameliorate the effects of tibial dyschondroplasia.
• Borenstein et al US 5,043,170 discloses the combination of Vitamin D3 and either 1 -alpha- hydroxycholecalciferol or 1 alpha, 25-dihydroxycholecalciferol to improve egg strength and leg strength in laying hens and older hens.
• Fleshner-Barak discloses administration of bisphosphonate compound and natural vitamin D derivative such as 1 ,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3, or 25-OH vitamin D3.
• Daifotis et al. disclose inhibiting bone resorption by a combination of at least one bisphosphonate compound and from about 100 IU to about 60,000 IU of a no activated metabolite of vitamin D2 and/or vitamin D3.
• Vitamin D metabolite means any metabolite of Vitamin D as for example 25-hydroxy vitamin D3, 1 ,25-dihydroxy vitamin D3 or 24,25-dihydroxy vitamin D3.
• 25-OH D3 refers specifically to 25-hydroxy vitamin D3.
• Pesttry is meant to include turkeys, ducks and chickens (including but not limited to broiler chicks, layers, breeders).
• Canthaxanthin and 25-OH D3 may be obtained from any source, and a composition thereof may be prepared using convenient technology.
• one or more feed compositions suitable for poultry use are provided to administer canthaxanthin or 25-OH D3 and combinations thereof as nutrients to improve hatchability, fertility and lower embryo mortality during the first phase of embryo development.
• a poultry feed which comprises from about 10 ⁇ g/kg to about 100 ⁇ g/kg of 25-OH D3 and/or from about 2 to 100 ppm canthaxanthin, preferably 2 to 10 ppm.
• a method of administering canthaxanthin and/or 25-OH D3 to poultry breeders is provided to improve hatchability, fertility and lower embryo mortality during the first phase of embryo development.
• the method for improving hatchability in poultry comprises administering to the animal in need of such treatment an amount of about 2 ppm to 100 ppm of canthaxanthin, preferably 2 to 10 ppm, and/or about 10 ⁇ g/kg to about 100 ⁇ g/kg of 25-OH D3.
• a premix composition for poultry feed comprising 25-hydroxy vitamin D3 and canthaxanthin is provided.
• Canthaxanthin and 25-hydroxy vitamin D3 are suitably administered together with the food.
• the term food as used herein comprises both solid and liquid food as well as drinking fluids such as drinking water.
• inventive ingredients can be added as a formulated powder to a premix containing other minerals, vitamins, amino acids and trace elements which is added to regular animal food and thorough mixing to achieve even distribution therein.
• a food premix may be prepared on the basis of regular food components by adding these active ingredients to such food components in higher concentration.
• canthaxanthin compound is available under the Trademark ROVIM IX® Hy-D® 1.25 % and canthaxanthin under the Trademark CAROPHYLL ⁇ Red.
• the composition also contains one or more of the following ingredients: Vitamin A, Vitamin E, Biotin, copper (e.g. as CuSO 4 ), zinc (e.g. as ZnSO 4 ), cobalt (e.g. as CoSO 4 ), selenium (e.g. as Na 2 SeO 3 ), iodine (e.g. as Kl), manganese (e.g. as MnSO 4 ) and/or calcium (e.g. as CaSO 4 ).
• Vitamin A Vitamin E
• Biotin copper
• copper e.g. as CuSO 4
• zinc e.g. as ZnSO 4
• cobalt e.g. as CoSO 4
• selenium e.g. as Na 2 SeO 3
• iodine e.g. as Kl
• manganese e.g. as MnSO 4
• calcium e.g. as CaSO 4
• Example 1 Effect of Carophyll Red (Canthaxanthin) on the productive and reproductive development of broiler chickens
• the birds underwent the recommended handling and feeding practices in the breeders' guide.
• To assess the fertility of the birds in each box an incubation session was carried out for one week, and using embryo diagnostics on the eggs that did not hatch, the percentage of fertility in each box was determined. The level of fertility was taken into consideration when distributing the treatments to each of the boxes, so that all treatments had the same level of fertility at the beginning of the study.
• the diet given to the birds was a standard feed for broiler chickens with the addition of the products that were tested.
• the feed met all nutritional requirements in relation to the developmental stage of the birds and the recommendations in the breeders' guide.
• the feed was entirely vegetable-based, using corn and Soya bran (Appendices 1 , 2 and 3).
• the experimental design was entirely random, with two treatments and six groups of 30 female and 3 male chickens.
• the laying rate was calculated weekly. To assess the weight of the eggs, specific gravity, average weight of eggs, yolk weight, albumen weight and the coloration of the yolk, all the eggs that were not considered suitable for incubation, collected on any given day, were used. Specific gravity was determined through the emersion of the eggs in saline solutions with densities of 1065; 1070; 1075; 1080; 1085; 1090 and 1095. The weighing of the eggs, yolks and albumen were carried out using a precision weighing scale (0.001 g). The coloration of the yolks was determined using the color fan from DSM Nutritional Products ® .
• the eggs were collected daily. They were then classified and marked with the number of the corresponding box. Those that were not considered suitable for incubation were stored for a maximum period of seven days in an air-conditioned room with temperature and humidity control. Incubation was carried out in a multi-stage incubator and on day 18, the eggs were transferred to a brooder. On day 21 the chicks were taken out of the brooder, vaccinated and classified. The eggs that did not hatch then underwent embryo diagnostics to evaluate fertility and the phase of embryonic mortality.
• Example 2 The test has been executed according to Example 1 , with the addition of ROVIMIX® Hy-D®.
• the treatments in example 2 were as follows:

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Zoology (AREA)
• Animal Husbandry (AREA)
• Food Science & Technology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Reproductive Health (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Pregnancy & Childbirth (AREA)
• Gynecology & Obstetrics (AREA)
• Nutrition Science (AREA)
• Fodder In General (AREA)
• Feed For Specific Animals (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=41562097

Family Applications (1)

Country Status (15)

Cited By (7)

Families Citing this family (2)

Citations (6)

Family Cites Families (4)

• 2009
  • 2009-11-11 RU RU2011124942/15A patent/RU2498613C2/ru active
  • 2009-11-11 ES ES09748799.5T patent/ES2439712T3/es active Active
  • 2009-11-11 EP EP09748799.5A patent/EP2358214B1/en not_active Revoked
  • 2009-11-11 WO PCT/EP2009/064963 patent/WO2010057811A2/en active Application Filing
  • 2009-11-11 MX MX2011005239A patent/MX2011005239A/es active IP Right Grant
  • 2009-11-11 CN CN201410791078.XA patent/CN104585500A/zh active Pending
  • 2009-11-11 JP JP2011535997A patent/JP2012509253A/ja active Pending
  • 2009-11-11 PL PL09748799T patent/PL2358214T3/pl unknown
  • 2009-11-11 BR BRPI0913531-6A patent/BRPI0913531B1/pt active IP Right Grant
  • 2009-11-11 AU AU2009317402A patent/AU2009317402B2/en active Active
  • 2009-11-11 US US13/128,275 patent/US20110224306A1/en not_active Abandoned
  • 2009-11-11 KR KR1020117011293A patent/KR20110095270A/ko not_active Application Discontinuation
  • 2009-11-11 SG SG2011016557A patent/SG169565A1/en unknown
  • 2009-11-11 CN CN2009801462363A patent/CN102215700A/zh active Pending
  • 2009-11-11 CA CA2737680A patent/CA2737680C/en active Active
• 2011
  • 2011-03-11 PH PH12011500511A patent/PH12011500511B1/en unknown
• 2013
  • 2013-09-23 US US14/034,384 patent/US20140024626A1/en not_active Abandoned
• 2017
  • 2017-01-23 US US15/413,254 patent/US20170128466A1/en not_active Abandoned

Patent Citations (6)

Also Published As

Similar Documents

Legal Events